Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022862 · ClinicalTrials.gov registry record · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
A NA study of Latent Tuberculosis, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- NA
- Development phase
- 399
- Enrollment target
- 1
- Study location
NCT05022862: Recruiting NA study of Latent Tuberculosis, sponsored by Johns Hopkins University.
NCT05022862 is a NA study of Latent Tuberculosis that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 399 participants, below the 1,126-participant average among 5 other Latent Tuberculosis trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022862, a NA study of Latent Tuberculosis, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- NA
- Development phase
- 399 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.
Primary Outcome
The primary outcome measure, completion of treatment for latent TB, will be assessed for all participants through MEMS caps. A participant will be considered to have completed treatment for study purposes if he/she takes 80% of the prescribed doses of medication, as determined by MEMS caps (i.e., 10 of 12 doses for participants prescribed weekly doses of rifapentine and isoniazid; 96 of 120 doses for participants prescribed daily doses of rifampin; 67 of 84 doses of daily isoniazid and rifampin
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Video Directly Observed Therapy alone
- BEHAVIORAL Video Directly Observed Therapy plus Financial Incentives
Study Locations (1)
Maryland
- Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2027-12-01 |
| Phase | NA |
What NCT05022862 shows while recruiting
NCT05022862 is an interventional study that assigns participants to a tested intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap, below the 1,126-participant average among 5 other Latent Tuberculosis trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Latent Tuberculosis appearing as the primary indexed condition, and to 3 interventions - of which Usual Care is the first listed.
NCT05022862 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05022862 about?
NCT05022862 is a clinical study titled "Economic Incentives and vDOT for Latent Tuberculosis Infection". The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruit...
What is the current status of trial NCT05022862?
This trial is currently recruiting. It is a NA study. The enrollment target is 399 participants. The study started on 2022-02-07. Estimated completion is 2027-12-01.
What conditions does trial NCT05022862 study?
This clinical trial studies the following conditions: Latent Tuberculosis.
What interventions are being tested in trial NCT05022862?
The interventions under investigation include: Usual Care (BEHAVIORAL), Video Directly Observed Therapy alone (BEHAVIORAL), Video Directly Observed Therapy plus Financial Incentives (BEHAVIORAL).
Who is sponsoring clinical trial NCT05022862?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05022862 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Latent Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brief Educational Video for Patients Prescribed LTBI Treatment
ACTIVE NOT RECRUITING · NA
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
RECRUITING · Phase 2
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Immune Response to Mycobacterium Tuberculosis Infection
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI